Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment

Massimiliano Castellazzi, Serena Delbue, Francesca Elia, Matteo Gastaldi, Diego Franciotta, Roberta Rizzo, Tiziana Bellini, Roberto Bergamaschi, Enrico Granieri, Enrico Fainardi

Research output: Contribution to journalArticle

Abstract

Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system. Natalizumab, a humanized anti-α4 integrin monoclonal antibody, is a highly effective treatment approved for MS. An association between MS and an exposure to Epstein-Barr Virus (EBV) sustained by the levels of antiviral capsid antigen (VCA) and anti-Epstein-Barr nuclear antigen-1 (EBNA-1) IgG has been described. Our goal was to verify the utility of EBV-specific IgG as a marker in Natalizumab treated MS. Twenty patients (17 female and 3 male) in treatment with Natalizumab were enrolled. Serum levels of anti-VCA and anti-EBNA-1 IgG were determined and expressed as arbitrary units (AU) before treatment and every three months for 21 months of therapy. Anti-VCA IgG levels were increased at the 15th month (235410 ± 196712 AU) comparing with the 3rd (98146 ± 47145 AU) and the 6th (109866 ± 52270 AU) months of therapy p

Original languageEnglish
Article number901312
JournalDisease Markers
Volume2015
DOIs
Publication statusPublished - 2015

    Fingerprint

ASJC Scopus subject areas

  • Biochemistry, medical
  • Clinical Biochemistry
  • Molecular Biology
  • Genetics

Cite this

Castellazzi, M., Delbue, S., Elia, F., Gastaldi, M., Franciotta, D., Rizzo, R., Bellini, T., Bergamaschi, R., Granieri, E., & Fainardi, E. (2015). Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment. Disease Markers, 2015, [901312]. https://doi.org/10.1155/2015/901312